cancer_treatment
The latest news about cancer_treatment: headlines, AI summaries and the full story from every source.
- FDA Expands Approval of ImmunityBio's Anktiva to Include Early-Stage Bladder Cancer
- Florida Cancer Specialists Contributes to FDA Approvals for Breast and Pancreatic Cancer Treatments
- FDA Approves Genentech's Tecentriq as Adjuvant Treatment for Stage III dMMR Colon Cancer
- Pfizer's Tukysa Approved by FDA for Front-Line Breast Cancer Treatment
- Deerfield Announces Fourth Annual AML Summit and ASH Peter Steelman Scholar Award Recipient
- BioNTech Terminates Colorectal Cancer Vaccine Trial Amid Efficacy Concerns
- BlossomHill Therapeutics Shares Rise After Updated Trial Data for BH-30643
- Moderna and Merck Announce Positive Phase 3 Trial Results for Personalized mRNA Cancer Vaccine
- Moderna Shares Surge Over 176% on Positive Phase 3 Melanoma Trial Data
- Eli Lilly's Olomorasib Receives FDA Breakthrough Therapy Designation for Pancreatic Cancer
- Karyopharm's Xpovio Fails Phase 3 Trial for Endometrial Cancer, Shares Plummet
- Pfizer's Talzenna/Xtandi Combo Receives FDA Priority Review for Prostate Cancer
- Pfizer Announces FDA Approval for PADCEV Plus Keytruda Combination Therapy for Muscle-Invasive Bladder Cancer
- Merck Reports Positive Late-Stage Trial Results for Keytruda
- Eli Lilly Announces Positive Phase 3 Results for Jaypirca Combination Therapy in Relapsed or Refractory CLL/SLL
- Merck Receives FDA Approval for KEYTRUDA Combination Therapy in Renal Cell Carcinoma and Announces Acquisition of Targan
- Summit Therapeutics Reports Positive Phase III Overall Survival Data for Ivonescimab in Advanced NSCLC
- FDA Expands Approval of Agilent's Diagnostic Test for Keytruda Patients
- Amgen Receives EU Approval for Imdelltra in Treating Small Cell Lung Cancer
- CytomX Reports Q4 2025 Earnings and Phase I Trial Data for Varseta-M
- Bicara (BCAX) Q4 2025 Earnings Call Summary
- Merck's Phase 3 TroFuse-005 Trial for Endometrial Cancer Meets Primary Endpoints
- Lantern Pharma Provides Q1 2025 Earnings Update
- Regeneron Announces Failure in Late-Stage Trial of Libtayo Combination Therapy